Dr. med. Jenny Stritzelberger

Department of Radiation Oncology Department of Neurology

Antiseizure medication and perceived “fair” cost allocation: A factorial survey among neurologists, persons with epilepsy, their relatives, and a control group (2022) Stritzelberger J, Walther K, Olmes D, Gollwitzer S, Graf W, Welte T, Lang J, et al. Journal article Resection of dominant fusiform gyrus is associated with decline of naming function when temporal lobe epilepsy manifests after the age of five: A voxel-based lesion-symptom mapping study (2022) Reindl C, Allgäuer A, Kleiser B, Onugoren MD, Lang J, Welte T, Stritzelberger J, et al. Journal article Effect of the AMPA Receptor Inhibitor Perampanel in Combination Therapy with ionizing Radiation on Glioblastoma Cells and Fibroblasts (2021) Knabe A, Stritzelberger J, Fietkau R, Distel L Conference contribution Alpha power decrease in quantitative EEG detects development of cerebral infarction after subarachnoid hemorrhage early (2021) Müller T, Gollwitzer S, Hopfengartner R, Rampp S, Lang J, Stritzelberger J, Madzar D, et al. Journal article The impact of the coronavirus disease (COVID-19) pandemic on outpatient epilepsy care: An analysis of physician practices in Germany (2021) Müller T, Kostev K, Gollwitzer S, Lang J, Stritzelberger J, Westermayer V, Reindl C, Hamer H Journal article Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany (2021) Lang J, Kostev K, Reindl C, Müller T, Stritzelberger J, Gollwitzer S, Westermayer V, et al. Journal article Anti-seizure medication is not associated with an increased risk to develop cancer in epilepsy patients (2021) Stritzelberger J, Lang J, Mueller TM, Reindl C, Westermayer V, Kostev K, Hamer H Journal article Ex vivo radiosensitivity is increased in non-cancer patients taking valproate (2020) Stritzelberger J, Lainer J, Gollwitzer S, Graf W, Jost T, Lang J, Müller T, et al. Journal article Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine (2018) Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F Journal article Temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine (2016) Stritzelberger J, Distel T, Fietkau R, Putz F Conference contribution